RecruitingPhase 3NCT03627013

Custodiol-N Solution Compared With Custodiol Solution in Organ Transplantation (Kidney, Liver and Pancreas)

A Prospective, Randomized, Single Blind, Multicentre Phase III Study on Organ Preservation With Custodiol-N Solution Compared With Custodiol Solution in Or-gan Transplantation (Kidney, Liver and Pancreas)


Sponsor

Dr. F. Köhler Chemie GmbH

Enrollment

362 participants

Start Date

May 23, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

Synopsis Title of Study A prospective, randomized, single blind multicentre phase III study on organ preservation with Custodiol-N compared with Custodiol solution in organ transplantation (kidney, liver and pancreas) Protocol number: CL-N-KLP-TX-III/07-AT/17 Trial design The study design is a prospective, randomized, single blind, multicentre, phase III comparison study of organ perfusion intended to demonstrate non-inferiority of Custodiol-N against Custodiol in organ transplantation of kidney, combined kidney-pancreas and liver. Intended duration of study The overall duration for the trial is expected to be approximately 30 months. The du-ration of the trial for each subject is expected to be 3 months (transplantation and a follow-up period of 90 days). Purpose of the study The objective of this investigation is to demonstrate non-inferiority of graft preservation with Custodiol-N compared to Custodiol with respect to both graft function and injury after transplantation of kidney, liver or combined kidney-pancreas. Patient selection The study population will be selected from patients who will undergo kidney, liver or combined kidney-pancreas transplantation. Patients of each gender will be included in the study. Planned number of patients (recipients) In total N=362 including: Kidney 242 (including approx. 30 combined kidney-pancreas) Liver 120


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is comparing two solutions used to preserve kidneys, livers, and pancreases during organ transplantation — the standard solution (Custodiol) versus a newer improved solution (Custodiol-N) — to see which better protects organs during the transplant process. **You may be eligible if...** - You are an adult (18 years or older) organ donor (deceased or living) whose kidneys, liver, or pancreas are being donated - OR you are an adult (18 years or older) waiting to receive a kidney, liver, or kidney-pancreas transplant - You or your representatives have provided signed informed consent before transplantation **You may NOT be eligible if...** - You are under 18 years old - You or your legal representative are unable or unwilling to provide informed consent - You have specific medical conditions that the transplant team determines make you ineligible Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCustodiol-N Solution

Perfusion

DRUGCustodiol HTK Solution

Perfusion


Locations(4)

Medical University Graz

Graz, Austria

Medical University Innsbruck

Innsbruck, Austria

Ordensklinikum Linz

Linz, Austria

Medical University Vienna

Vienna, Austria

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03627013


Related Trials